Sung Yon Mi, Lee Kyung Soo, Kim Byung-Tae, Choi Joon Young, Shim Young Mog, Yi Chin A
Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
J Nucl Med. 2006 Oct;47(10):1628-34.
The purpose of our study was to assess the usefulness of integrated PET/CT using 18F-FDG for distinguishing thymic epithelial tumors according to the World Health Organization (WHO) classification.
Thirty-three patients (age range, 34-68 y; mean age, 54.6 y) with thymic epithelial tumors, who underwent both integrated PET/CT and enhanced CT, were included. The clinicopathologic stages, maximum standardized uptake values (SUVs), and uptake patterns of tumors on integrated PET/CT images, and various enhanced CT findings, are described according to the simplified (low-risk [types A, AB, and B1] and high-risk [types B2 and B3] thymomas and thymic carcinomas) subgroups of the WHO classification. Discriminant analysis was performed to determine the relative capabilities of integrated PET/CT and enhanced CT findings to differentiate tumor subgroups.
Tumors included 8 low-risk thymomas, 9 high-risk thymomas, and 16 thymic carcinomas. The maximum SUVs of high-risk thymomas (P < 0.001) and low-risk thymomas (P < 0.001) were found to be significantly lower than those of thymic carcinomas. Homogeneous 18F-FDG uptake within tumors was more frequently seen in thymic carcinomas than in high-risk thymomas (P = 0.027) or low-risk thymomas (P = 0.001). The uptake pattern (homogeneous vs. heterogeneous) on integrated PET/CT images and the presence of mediastinal fat invasion on enhanced CT images were found to be useful for differentiating tumor subgroups. In addition, integrated PET/CT helped detect lymph node metastases, which were not identified on enhanced CT in 2 patients.
Integrated PET/CT was found to be useful for differentiating subgroups of thymic epithelial tumors and for staging the extent of the disease.
我们研究的目的是评估使用18F-FDG的PET/CT融合成像在根据世界卫生组织(WHO)分类区分胸腺上皮肿瘤方面的效用。
纳入33例接受了PET/CT融合成像和增强CT检查的胸腺上皮肿瘤患者(年龄范围34 - 68岁;平均年龄54.6岁)。根据WHO分类的简化亚组(低风险[A、AB和B1型]和高风险[B2和B3型]胸腺瘤及胸腺癌)描述肿瘤的临床病理分期、PET/CT融合图像上肿瘤的最大标准化摄取值(SUV)和摄取模式,以及各种增强CT表现。进行判别分析以确定PET/CT融合成像和增强CT表现区分肿瘤亚组的相对能力。
肿瘤包括8例低风险胸腺瘤、9例高风险胸腺瘤和16例胸腺癌。发现高风险胸腺瘤(P < 0.001)和低风险胸腺瘤(P < 0.001)的最大SUV显著低于胸腺癌。胸腺癌中肿瘤内18F-FDG摄取均匀的情况比高风险胸腺瘤(P = 0.027)或低风险胸腺瘤(P = 0.001)更常见。发现PET/CT融合图像上的摄取模式(均匀与不均匀)以及增强CT图像上纵隔脂肪侵犯的存在有助于区分肿瘤亚组。此外,PET/CT融合成像有助于检测淋巴结转移,2例患者的淋巴结转移在增强CT上未被发现。
发现PET/CT融合成像在区分胸腺上皮肿瘤亚组和确定疾病范围分期方面有用。